Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
